The Asian Fund for Cancer Research and the US Chinese Anti-Cancer Association jointly awarded six outstanding Chinese cancer researchers in the early stages of their careers with the 2018 USCACA-AFCR Young Investigator Award. Scholars received a certificate for the Award and a cheque in the amount of U.S. $1,000 in…...
New Faces
The Asian Fund for Cancer Research is pleased and honored to have recently both expanded its board of directors and established a council of advisors. Franck Le Deu, a senior partner in the Hong Kong office of McKinsey & Company, where he leads the consultancy’s pharmaceuticals and medical products practice…...
The Pathfinder
The “Ras/Raf/MEK/ERK pathway” is a mouthful. Oncologists will tell you the same thing. But behind the long phrase is an important field of cancer research—one in which Jiancheng Hu, Ph.D., a scientist supported by the Asian Fund for Cancer Research since 2017, is a renowned expert. Ras is a family…...
Confronting Cancer Together—as One City
The Asian Fund for Cancer Research was proud to have been among the 50-plus organizations and companies to have participated in the Hong Kong Anti-Cancer Society’s Hong Kong Cancer Day activities, held Sunday, 9 December 2018. A full slate of family-friendly programming was presented to nearly 3,000 participants, including food,…...
New therapeutic avenue in the fight against chronic liver disease
Chronic liver disease is known as the silent killer, showing no obvious symptoms until the disease has progressed to an advanced stage. Therefore, making a proper diagnosis in the early stage of disease progression a clinical challenge. An international team of researchers, affiliated with UNIST, has identified a novel route that regulates the…...
Molecular profiling could catch lung cancer early and lead to new treatments
Before lung cancer develops, precancerous lesions are found in the airway, but only some of these will actually become lung cancer, while others will disappear or remain benign without becoming harmful. Under the microscope, the lesions look the same, making it difficult to know which lesions to treat. A new…...
Antibodies to a retina protein to be used as a kidney cancer marker
Tumors can be benign or malignant. Benign tumors can evolve into malignant ones. Around 90 to 93% of all kidney growths turn out to be malignant, and there are currently no effective methods for early diagnostics. The initial stages of kidney cancer have no signs or specific symptoms, so patients are often…...
Making Progress
This past fall saw considerable progress in the development of GBM AGILE, the brain cancer clinical trial initiative whose early-stage planning has long been supported by the Asian Fund for Cancer Research. Not only was an acting head hired to run the Global Coalition for Adaptive Research (GCAR), the non-profit…...
What happens if chemotherapy does not work?
Chemotherapy is used by doctors to either as a first-line therapy or in combination with other treatments, such as surgery, to treat cancer. If chemotherapy does not work, a person may need to consider other treatment options. Signs that the cancer is not responding to chemotherapy include the growing or spreading…...
